
Market Analysis
AARD: FDA Hold Lifted at Night, Trial Data at Dawn, Shares Down 65%
Aardvark rose 48% pre-market after the FDA lifted its clinical hold, then closed down 65% once data from its stopped Phase 3 trial came out.
Lead story · No. 038

Market Analysis
Aardvark rose 48% pre-market after the FDA lifted its clinical hold, then closed down 65% once data from its stopped Phase 3 trial came out.
Market Analysis
AI OKTO declared a $3.50 special dividend on a $4.25 stock and agreed to sell a ship to a company its CEO controls. It closed up 183%.
Market Analysis
BOLT opened 66.6% higher on October 23 after acquiring Prana. The $120 million financing was expected to close October 26; legacy holders would own 6.9% on the stated diluted basis.
Reading the session
Learn how gap up and gap down are calculated, how opening gaps differ from premarket changes, and why the reference price and timestamp matter.
Data study
A look at 671 US stock gap-ups of 20% or more from July 1 to October 2, 2026: when the 4:00 a.m.–8:00 p.m. ET high printed, split by gap size, price and how the day ended.
Company disclosures
Understand stock offerings, dilution, and reverse splits. Distinguish new issuance from resale and check transaction stages before interpreting share counts.
Research process
Research why a stock moved using company announcements, SEC filings, and a source-linked timeline. Separate confirmed events from explanations and unknowns.
Retrospective data built after the session from stored records, with links to the original sources. Not real-time, not investment advice and not a recommendation to buy or sell any security.